High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19

Abstract

MS has received grant support from Astellas Pharmaceuticals and Biotest to her institution, Saarland University, outside the area of work commented on here, and honoraria for lectures from Biotest and Novartis. SLB has received travel grants and speaker fees from Astellas Pharmaceuticals, Becton Dickinson, Novartis, Pfizer, and Shionogi outside the area of work commented on here, and participated on advisory boards of Pfizer (pertaining to ceftazidime/avibactam) and Shionogi (pertaining to cefiderocol).

Plasma procurement and plasma product safety in light of the COVID‐19 pandemic from the perspective of the plasma industry

“…The antibody treatment approach has thus far demonstrated efficacy at an earlier stage, namely pre‐hospitalization, of the disease through trials with monoclonal antibodies. This was not something that was so apparent when the clinical trial was designed and warrants more research for better understanding [ 54 , 55 , 56 , 57 ].…”

Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2

“…The study has also identified an increase in adverse events (particularly respiratory failure) in patients with neutralizing antibodies receiving the HIG, versus those without antibodies [19] . This observation raises questions on the possible negative effects of the administration of anti-SARS-CoV-2 HIG in patients with pre-existing neutralizing antibodies [87] . These adverse events do not seem specific to a particular brand of anti-SARS-CoV-2 HIG since this study used 4 different products.…”

Demultiplexing Ig Repertoires by Parallel mRNA/DNA Sequencing Shows Major Differential Alterations in Severe COVID-19

“…10,11 Accordingly, patients at this stage of strong viral burden and inflammation become unresponsive to passive immunotherapy with specific mAbs or convalescent plasma. 12,13 Immune dysfunction is clearly multifactorial in ICU patients, with atypical myeloid cell expansion and increased levels of pro-inflammatory cytokines correlating with T cell lymphocytopenia and a broad T cell activation including Th1, Th2, Th17, and MAIT cells. [14][15][16][17][18][19] Cellular anomalies are also present on the B-cell side, and differ between patients with mild COVID-19 and ICU patients, the latter showing an increase of blood plasma cells and of double-negative (DN) [IgD neg , CD27 neg ] B-cells suggesting extra-follicular B-cell activation.…”